West Michigan Advisors LLC Boosts Stake in Stryker Co. (NYSE:SYK)

West Michigan Advisors LLC grew its stake in shares of Stryker Co. (NYSE:SYK) by 1.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 8,675 shares of the medical technology company’s stock after acquiring an additional 102 shares during the period. West Michigan Advisors LLC’s holdings in Stryker were worth $3,131,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. US Bancorp DE grew its position in shares of Stryker by 0.5% during the 4th quarter. US Bancorp DE now owns 182,825 shares of the medical technology company’s stock valued at $65,829,000 after acquiring an additional 976 shares during the period. Noesis Capital Mangement Corp grew its position in shares of Stryker by 1.0% during the 4th quarter. Noesis Capital Mangement Corp now owns 64,143 shares of the medical technology company’s stock valued at $23,095,000 after acquiring an additional 650 shares during the period. SVB Wealth LLC bought a new position in shares of Stryker during the 4th quarter valued at approximately $11,321,000. Flputnam Investment Management Co. grew its position in shares of Stryker by 137.6% during the 4th quarter. Flputnam Investment Management Co. now owns 92,137 shares of the medical technology company’s stock valued at $33,174,000 after acquiring an additional 53,366 shares during the period. Finally, Dynasty Wealth Management LLC grew its position in shares of Stryker by 9.1% during the 4th quarter. Dynasty Wealth Management LLC now owns 7,611 shares of the medical technology company’s stock valued at $2,740,000 after acquiring an additional 633 shares during the period. 77.09% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on SYK shares. The Goldman Sachs Group raised their price objective on shares of Stryker from $384.00 to $427.00 and gave the stock a “neutral” rating in a report on Thursday, January 30th. Truist Financial raised their price objective on shares of Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a report on Thursday, January 30th. StockNews.com downgraded shares of Stryker from a “buy” rating to a “hold” rating in a report on Tuesday. JMP Securities reaffirmed a “market perform” rating on shares of Stryker in a report on Tuesday, February 18th. Finally, Canaccord Genuity Group raised their price objective on shares of Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a report on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $422.15.

Insider Activity

In related news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now owns 14,895 shares in the company, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company’s stock.

Stryker Stock Performance

Stryker stock opened at $386.55 on Friday. The firm’s fifty day moving average price is $380.50 and its 200-day moving average price is $370.92. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The stock has a market cap of $147.50 billion, a P/E ratio of 49.81, a price-to-earnings-growth ratio of 2.93 and a beta of 0.96. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the previous year, the company posted $3.46 EPS. On average, equities research analysts expect that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 0.87%. The ex-dividend date is Monday, March 31st. Stryker’s dividend payout ratio (DPR) is currently 43.30%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.